ERBB2 and breast cancer: Recently, a 7% heterogeneity rate in HER2-positive/negative status between major and minor foci of multifocal or multicentric BC has been reported [42]; however, there is insufficient strong evidence supporting HER2 testing in all foci of multifocal disease.